Otsuka Holdings Co., Ltd. Stock

Equities

4578

JP3188220002

Pharmaceuticals

Market Closed - Japan Exchange 02:00:00 2024-05-31 am EDT 5-day change 1st Jan Change
6,474 JPY +3.48% Intraday chart for Otsuka Holdings Co., Ltd. +4.69% +22.40%
Sales 2024 * 2,206B 14.02B Sales 2025 * 2,183B 13.87B Capitalization 3,512B 22.32B
Net income 2024 * 226B 1.44B Net income 2025 * 240B 1.52B EV / Sales 2024 * 1.37 x
Net cash position 2024 * 497B 3.16B Net cash position 2025 * 646B 4.11B EV / Sales 2025 * 1.31 x
P/E ratio 2024 *
15.2 x
P/E ratio 2025 *
14.4 x
Employees 34,388
Yield 2024 *
1.82%
Yield 2025 *
1.87%
Free-Float 81.39%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.48%
1 week+4.69%
1 month-1.33%
3 months+6.94%
6 months+13.10%
Current year+22.40%
More quotes
1 week
6 075.00
Extreme 6075
6 485.00
1 month
6 075.00
Extreme 6075
6 708.00
Current year
5 030.00
Extreme 5030
6 845.00
1 year
4 857.00
Extreme 4857
6 845.00
3 years
3 827.00
Extreme 3827
6 845.00
5 years
3 224.00
Extreme 3224
6 845.00
10 years
2 918.00
Extreme 2918
6 845.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 74 08-07-07
Director of Finance/CFO 62 15-02-28
Chairman 59 08-07-07
Members of the board TitleAgeSince
Chief Executive Officer 74 08-07-07
Chairman 59 08-07-07
Director/Board Member 57 17-03-29
More insiders
Date Price Change Volume
24-05-31 6,474 +3.48% 3,029,000
24-05-30 6,256 +2.52% 1,140,000
24-05-29 6,102 -0.81% 770,400
24-05-28 6,152 -.--% 669,000
24-05-27 6,152 -0.52% 543,600

Delayed Quote Japan Exchange, May 31, 2024 at 02:00 am EDT

More quotes
Otsuka Holdings Co, Ltd. is a holding company organised around 4 areas of activity: - manufacture and sale of pharmaceutical products (65.2% of sales): prescription drugs and intravenous solutions mainly for the treatment of central nervous system disorders, cancer, cardiovascular, gastrointestinal and ophthalmic diseases. In addition, the group sells diagnostic products and medical devices; - manufacture and sale of nutraceutical products (25.1%): functional foods and beverages, OTC products, nutritional supplements; - production of mineral waters, beverages and foods (2.1%); - other (7.5%): manufacture of functional chemicals and fine chemicals, provision of logistics services, manufacture of electronic products, etc. Net sales by source of income are divided between sales of products (93.8%), sales of licences and royalties (1.8%) and other (4.4%). Net sales are distributed geographically as follows: Japan (43.2%), North America (34%),
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
6,474 JPY
Average target price
6,473 JPY
Spread / Average Target
-0.02%
Consensus